The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
出版年份 2019 全文链接
标题
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
作者
关键词
Cancer, Diarrhea, ErbB receptor, Tyrosine kinase inhibitor
出版物
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-01-24
DOI
10.1007/s10549-018-05102-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY
- (2017) B. Besse et al. ANNALS OF ONCOLOGY
- The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer
- (2016) Xin Gao et al. Expert Review of Anticancer Therapy
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Abstract P5-19-04: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy
- (2015) Devika Gajria et al. CANCER RESEARCH
- Prophylactic use of antidiarrheal agents to control diarrhea associated with lapatinib therapy in breast cancer patients.
- (2015) Muhammad Omer Jamil et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
- (2014) George Dranitsaris et al. BREAST CANCER RESEARCH AND TREATMENT
- Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions
- (2014) Solange Peters et al. CANCER TREATMENT REVIEWS
- Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors
- (2014) V. Hirsh et al. Current Oncology
- Guidance on the management of diarrhoea during cancer chemotherapy
- (2014) Jervoise Andreyev et al. LANCET ONCOLOGY
- Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study
- (2013) Rachel C. Jankowitz et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies
- (2013) Woondong Jeong et al. CURRENT PROBLEMS IN CANCER
- Diarrhea associated with afatinib: an oral ErbB family blocker
- (2013) James Chih-Hsin Yang et al. Expert Review of Anticancer Therapy
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of TKI-induced diarrhea in cancer patients
- (2013) Joanne M. Bowen Current Opinion in Supportive and Palliative Care
- Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea
- (2012) Joanne M. Bowen et al. CANCER BIOLOGY & THERAPY
- Activity-based kinase profiling of approved tyrosine kinase inhibitors
- (2012) Daisuke Kitagawa et al. GENES TO CELLS
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- (2012) Tudor Ciuleanu et al. LANCET ONCOLOGY
- Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib
- (2011) IRIS AMITAY-LAISH et al. Dermatologic Therapy
- Crofelemer for the treatment of secretory diarrhea
- (2011) Jessica Cottreau et al. Expert Review of Gastroenterology & Hepatology
- The Intestinotrophic Peptide, GLP-2, Counteracts the Gastrointestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, and Cisplatin
- (2010) Andreas Rosén Rasmussen et al. DIGESTIVE DISEASES AND SCIENCES
- Structure-Function Analysis of Nucleolin and ErbB Receptors Interactions
- (2009) Keren Farin et al. PLoS One
- EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
- (2009) Tae Won Jang et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function
- (2008) D. F. McCole et al. Acta Physiologica
- Evaluation and Management of Treatment-Related Diarrhea in Patients with Advanced Cancer: A Review
- (2008) Nathan I. Cherny JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
- (2008) Yohann Loriot et al. Nature clinical practice. Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started